Pargyline

• UNSPSC Description:

  Pargyline is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline has antihypertensive and anticancer activities[1][2][3]. Pargyline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

• Target Antigen:

  Monoamine Oxidase

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cancer; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Pargyline.html

• Purity:

  99.92

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  C#CCN(C)CC1=CC=CC=C1

• Molecular Weight:

  159.23

• References & Citations:

  [1]C J Fowler, et al. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. Biochem Pharmacol. 1982 Nov 15;31(22):3555-61.|[2]Hyung Tae Lee, et al. Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells. Oncol Rep. 2013 Oct;30(4):1587-92.|[3]Fuentes JA, et al. Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur J Pharmacol. 1979 Jul 15;57(1):21-7.J Parkinson Dis. 2020;10(2):523-542.|Neural Regen Res. 2021;16:1660-70.|Parkinsons Dis-us. 2022.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  Launched

• CAS Number:

  555-57-7